Ge Long Hui A P P·2026-01-27 09:07Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 1: Product Development - HRS-5346 is an oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], which is a significant independent risk factor for atherosclerotic cardiovascular diseases [1] - There are currently no similar products approved for market in both domestic and international markets [1] - The cumulative research and development investment for HRS-5346 has reached approximately 76.3 million yuan (unaudited) [1] Group 2: Market Context - Elevated Lp(a) levels are the most common single-gene lipid disease globally, with prevalence rates in Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41%, respectively [1] - Targeting Lp(a) through lipid-lowering therapies represents a significant breakthrough direction in the prevention and treatment of cardiovascular diseases [1]